Education
About Us
Working with TipRanks
Follow Us
Zenas BioPharma, Inc. (ZBIO)
NASDAQ:ZBIO
ZBIO Stock Chart & Stats
$22.48
-$0.05(-0.51%)
At close: 4:00 PM EST
$22.48
-$0.05(-0.51%)
Day’s Range― - ―
52-Week Range$6.11 - $44.60
Previous CloseN/A
Volume96.53K
Average Volume (3M)1.07M
Market Cap
$1.21B
Enterprise Value$775.18M
Total Cash (Recent Filing)$290.88M
Total Debt (Recent Filing)$798.00K
Price to Earnings (P/E)―
Beta0.36
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.90
Shares Outstanding53,679,165
10 Day Avg. Volume694,313
30 Day Avg. Volume1,074,154
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.10
Price to Sales (P/S)68.44
P/FCF Ratio-2.86
Enterprise Value/Market Cap0.64
Enterprise Value/Revenue51.68
Enterprise Value/Gross Profit-23.47
Enterprise Value/Ebitda-3.96
Forecast
1Y Price Target
$41.20Price Target Upside83.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-4.45
Revenue Forecast (FY)$36.26M
Bulls Say, Bears Say
Bulls Say
Administration And Patient PreferenceAnalyst highlights obexelimab's at-home subcutaneous dosing, faster B-cell recovery, and the ability to pause treatment for vaccinations or procedures, which could drive patient preference and uptake versus intravenous alternatives.
Clinical Trial ResultsAnalyst notes that registrational Phase 3 INDIGO results showed a statistically significant reduction in IgG4-related disease flares and strong performance on key secondary measures, supporting regulatory approval prospects.
Commercial Opportunity And Physician InterestAnalyst reports strong interest from IgG4-related disease physicians in a B-cell inhibitory option and notes the market assigns little value to the company's IgG4 opportunity, implying upside if commercial uptake materializes.
Bears Say
Addressable Market LimitationsAnalyst notes obexelimab is focused on moderate and milder cases while an existing infusion therapy is considered necessary for severe multi-organ disease, constraining the drug's addressable market in the most serious patients.
Comparative Efficacy ConcernsAnalyst flags that although the Phase 3 trial met its primary endpoint, its efficacy fell short of a competing therapy's benchmark, which may limit investor enthusiasm and near-term catalysts.
Competitive Threat From Superior AgentsAnalyst warns that a competing cytolytic CD19 antibody with stronger efficacy could challenge obexelimab's market positioning despite its favorable safety and dosing profile.
Zenas BioPharma, Inc. News
ZBIO FAQ
What was Zenas BioPharma, Inc.’s price range in the past 12 months?
Zenas BioPharma, Inc. lowest stock price was $6.11 and its highest was $44.60 in the past 12 months.
What is Zenas BioPharma, Inc.’s market cap?
Zenas BioPharma, Inc.’s market cap is $1.21B.
When is Zenas BioPharma, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zenas BioPharma, Inc.’s earnings last quarter?
Zenas BioPharma, Inc. released its earnings results on Aug 12, 2025. The company reported -$1.25 earnings per share for the quarter, missing the consensus estimate of -$1.038 by -$0.212.
Is Zenas BioPharma, Inc. overvalued?
According to Wall Street analysts Zenas BioPharma, Inc.’s price is currently Undervalued.
Does Zenas BioPharma, Inc. pay dividends?
Zenas BioPharma, Inc. does not currently pay dividends.
What is Zenas BioPharma, Inc.’s EPS estimate?
Zenas BioPharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zenas BioPharma, Inc. have?
Zenas BioPharma, Inc. has 53,679,165 shares outstanding.
What happened to Zenas BioPharma, Inc.’s price movement after its last earnings report?
Zenas BioPharma, Inc. reported an EPS of -$1.25 in its last earnings report, missing expectations of -$1.038. Following the earnings report the stock price went up 1.705%.
Which hedge fund is a major shareholder of Zenas BioPharma, Inc.?
Currently, no hedge funds are holding shares in ZBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zenas BioPharma, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$41.20 (83.27% Upside)
$41.20 (83.27% Upside)
Blogger Sentiment
Bullish
ZBIO Sentiment 70%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
191.56%
12-Months-Change
Fundamentals
Return on Equity
-68.33%
Trailing 12-Months
Asset Growth
-20.18%
Trailing 12-Months
Company Description
Zenas BioPharma, Inc.
Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.
ZBIO Stock 12 Month Forecast
Average Price Target
$41.20
▲(83.27% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---